Baiyunshan's Penicillin Sodium Injection Achieves Generic Drug Equivalence

Stock News
Yesterday

Baiyunshan (00874) announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for its supplemental drug application. The 0.96g (1.6 million units) injection of penicillin sodium has passed the consistency evaluation for generic drug quality and efficacy. Penicillin sodium injection is used to treat various infections caused by susceptible bacteria, such as abscesses, bacteremia, pneumonia, and endocarditis. Penicillin is the preferred treatment for infections including hemolytic streptococcus infections, pneumococcal infections, non-penicillinase-producing staphylococcal infections, anthrax, tetanus, gas gangrene and other clostridial infections, syphilis (including congenital syphilis), leptospirosis, relapsing fever, diphtheria, and when combined with aminoglycosides for treating streptococcus viridans endocarditis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10